Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.

× No keyword cloud information.

13 in total

1. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

Authors: J M Edelberg; M Weissler; S V Pizzo
Journal: Biochem J Date: 1991-06-15 Impact factor: 3.857

2. Lipoprotein (a) levels do not influence the outcome of rt-PA therapy in acute myocardial infarction.

Authors: B Tranchesi; R Santos Filho; C Vinagre; B Caramelli; V Barbosa; O Gebara; G Belloti; F Pileggi; R Maranhão
Journal: Ann Hematol Date: 1991-04 Impact factor: 3.673

3. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein.

Authors: J M Edelberg; J J Enghild; S V Pizzo; M Gonzalez-Gronow
Journal: J Clin Invest Date: 1990-07 Impact factor: 14.808

4. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.

Authors: N W Boonmark; X J Lou; Z J Yang; K Schwartz; J L Zhang; E M Rubin; R M Lawn
Journal: J Clin Invest Date: 1997-08-01 Impact factor: 14.808

5. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans.

Authors: J-P Chretien; J Coresh; Y Berthier-Schaad; W H L Kao; N E Fink; M J Klag; S M Marcovina; F Giaculli; M W Smith
Journal: J Med Genet Date: 2006-07-13 Impact factor: 6.318

10. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.

Authors: X J Lou; N W Boonmark; F T Horrigan; J L Degen; R M Lawn
Journal: Proc Natl Acad Sci U S A Date: 1998-10-13 Impact factor: 11.205

Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.

1. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

2. Lipoprotein (a) levels do not influence the outcome of rt-PA therapy in acute myocardial infarction.

3. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein.

4. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.

5. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans.

6. Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control.

7. Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

8. Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus.

Review 9. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

10. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.